Takeda Pharmaceutical Company Limited EBIT

The latest EBIT for TKPHF is $650B as of June 2026. That compares with $440B in the prior-year period — up 46.1% year over year. That is above the Healthcare sector average of $130B. Investors often review this figure alongside Takeda Pharmaceutical Company Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, TKPHF's EBIT moved from $440B to $650B — a 46.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Takeda Pharmaceutical Company Limited's operating scale or balance-sheet position.

Against Healthcare companies, TKPHF currently prints $650B for EBIT, while the sector average sits near $130B. That is roughly 383.8% above the sector mean. Large gaps often invite a closer look at Takeda Pharmaceutical Company Limited's growth, margins, and balance sheet.

A EBIT figure of $650B for TKPHF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $130B. Explore the charts below for those layers of context.

After noting TKPHF's EBIT ($650B), review year-over-year change from $440B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.